Zeleniuch-Jacquotte A, Shore R E, Koenig K L, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim M Y, Rinaldi S, Kaaks R, Toniolo P
Department of Environmental Medicine, New York University School of Medicine, 650 First Avenue, New York, NY 10016, USA.
Br J Cancer. 2004 Jan 12;90(1):153-9. doi: 10.1038/sj.bjc.6601517.
We assessed the association of sex hormone levels with breast cancer risk in a case-control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2.49 (1.47-4.21), P(trend)=0.003 for oestradiol; 3.24 (1.87-5.58), P(trend)<0.001 for oestrone; 2.37 (1.39-4.04), P(trend)=0.002 for testosterone; 2.07 (1.28-3.33), P(trend)<0.001 for androstenedione; 1.74 (1.05-2.89), P(trend)<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31-0.82), P(trend)<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92-1.26 for testosterone; 1.15, 95% CI=0.95-1.39 for androstenedione and 1.06, 95% CI=0.90-1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production.
我们在一项巢式病例对照研究中,评估了性激素水平与乳腺癌风险之间的关联。该研究纳入了7054名纽约大学女性健康研究参与者,她们在入组时已绝经。研究包括297例在入组后6个月至12.7年期间确诊的病例和563名对照。每种激素和性激素结合球蛋白(SHBG)最高五分位数相对于最低五分位数的乳腺癌多变量优势比(OR)(95%置信区间(CI))如下:雌二醇为2.49(1.47 - 4.21),P(趋势)=0.003;雌酮为3.24(1.87 - 5.58),P(趋势)<0.001;睾酮为2.37(1.39 - 4.04),P(趋势)=0.002;雄烯二酮为2.07(1.28 - 3.33),P(趋势)<0.001;硫酸脱氢表雄酮(DHEAS)为1.74(1.05 - 2.89),P(趋势)<0.001;SHBG为0.51(0.31 - 0.82),P(趋势)<0.001。对191例在诊断前5至12.7年献血的病例进行的分析显示,结果与总体分析方向相同,尽管DHEAS和SHBG的趋势检验未达到统计学显著性。对95例病例及其在诊断后5年内进行第二次献血的匹配对照计算的激素和SHBG水平每年变化率幅度较小,病例组和对照组总体无差异。在调整与我们研究中风险关联最强的雌激素雌酮后,雄激素与风险之间的关联不再持续(睾酮的OR为1.08,95%CI = 0.92 - 1.26;雄烯二酮的OR为1.15,95%CI = 0.95 - 1.39;DHEAS的OR为1.06,95%CI = 0.90 - 1.26)。我们的结果支持这样的假设,即循环雌激素与乳腺癌风险之间的关联更可能是由于循环激素对癌症发展的影响,而不是肿瘤诱导的升高。它们还表明,雄激素对风险的贡献很大程度上是通过其作为雌激素产生底物的作用。